4.4 Article

Analgesic Use and Ovarian Cancer Risk: An Analysis in the Ovarian Cancer Cohort Consortium

Journal

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
Volume 111, Issue 2, Pages 137-145

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/jnci/djy100

Keywords

-

Categories

Funding

  1. Department of Defense Ovarian Cancer Research Program [W81XWH-12-1-0561]
  2. Breast Cancer Now
  3. Institute of Cancer Research (ICR)
  4. National Health Service
  5. National Cancer Institute (NCI) [K05CA154337]
  6. Office of Dietary Supplements (VITAL) [K05CA154337]
  7. Iowa Women's Health Study [R01 CA39742]
  8. Swedish Research Council
  9. Swedish Cancer Foundation
  10. Multiethnic Cohort Study [MEC] [UM1 CA164973]
  11. NIH/NCI [UM1 CA182876]
  12. Nurses' Health Study, Nurses' Health Study II [UM1 CA186107, P01 CA87969, UM1 CA176726, R01 CA67262]
  13. NIEHS Intramural Research Program [Z01-ES044005]
  14. National Heart, Lung, and Blood Institute, NIH/DHHS [HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, HHSN271201100004C]
  15. NCI Intramural Research Program
  16. NATIONAL CANCER INSTITUTE [ZIACP010152] Funding Source: NIH RePORTER
  17. NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES044005] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Background Aspirin use is associated with reduced risk of several cancers. A pooled analysis of 12 case-control studies showed a 10% decrease in ovarian cancer risk with regular aspirin use, which was stronger for daily and low-dose users. To prospectively investigate associations of analgesic use with ovarian cancer, we analyzed data from 13 studies in the Ovarian Cancer Cohort Consortium (OC3). Methods The current study included 758 829 women who at study enrollment self-reported analgesic use, among whom 3514 developed ovarian cancer. Using Cox regression, we assessed associations between frequent medication use and risk of ovarian cancer. Dose and duration were also evaluated. All statistical tests were two-sided. Results Women who used aspirin almost daily (6 days/wk) vs infrequent/nonuse experienced a 10% reduction in ovarian cancer risk (rate ratio [RR] = 0.90, 95% confidence interval [CI] = 0.82 to 1.00, P = .05). Frequent use (4 days/wk) of aspirin (RR = 0.95, 95% CI = 0.88 to 1.03), nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs; RR = 1.00, 95% CI = 0.90 to 1.11), or acetaminophen (RR = 1.05, 95% CI = 0.88 to 1.24) was not associated with risk. Daily acetaminophen use (RR = 1.28, 95% CI = 1.00 to 1.65, P = .05) was associated with elevated ovarian cancer risk. Risk estimates for frequent, long-term (10+ years) use of aspirin (RR = 1.15, 95% CI = 0.98 to 1.34) or nonaspirin NSAIDs (RR = 1.19, 95% CI = 0.84 to 1.68) were modestly elevated, although not statistically significantly so. Conclusions This large, prospective analysis suggests that women who use aspirin daily have a slightly lower risk of developing ovarian cancer (approximate to 10% lower than infrequent/nonuse)similar to the risk reduction observed in case-control analyses. The observed potential elevated risks for 10+ years of frequent aspirin and NSAID use require further study but could be due to confounding by medical indications for use or variation in drug dosing.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available